Sarah Boyce insider trades
Open-market stock purchases and sales by Sarah Boyce, Director at Contineum Therapeutics, Inc, from SEC Form 4 filings since Jan 1, 2015.
Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -29%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 26, 2026 | CTNM Contineum Therapeutics, Inc | Bought (not open market) | — |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc | Bought (not open market) | — |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | — |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $479K |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $6M |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $9M |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $1.3M |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $3M |
| Feb 27, 2026 | RNAM Avidity Biosciences, Inc | Sold (not open market) | $5.2M |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc | Sold | $463K |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc | Sold | $579K |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc | Sold | $619K |
| Dec 18, 2025 | RNA Avidity Biosciences, Inc | Sold (not open market) | — |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc | Bought (not open market) | — |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc | Sold (not open market) | $1.1M |
Companies traded
- CTNM Contineum Therapeutics, Inc: other filings, last Jun 26, 2026
- RNA Atrium Therapeutics, Inc: 29 sales, last Feb 27, 2026
- RNAM Avidity Biosciences, Inc: other filings, last Feb 27, 2026
- OABI OmniAb, Inc: 2 buys, last Jun 18, 2024
- LGND Ligand Pharmaceuticals Inc: other filings, last Nov 1, 2022
- BLI Berkeley Lights, Inc: 3 sales, last May 14, 2021
- AKCA Akcea Therapeutics, Inc: 1 sale, last Jul 15, 2019
- IONS Ionis Pharmaceuticals Inc: 4 sales, last Jan 16, 2018
- ISIS Isis Pharmaceuticals Inc: other filings, last Jan 15, 2015